Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Savara Inc./ 8-K

Current Report · Items 1.01, 9.01 · 8-K

Savara Inc.

SVRANASDAQEQUITYCurrent

Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On March 10, 2026, Savara Inc. (the “Company”) entered into an Agreement of Lease (the “Lease”) with ML7 Yardley Partners, LP (“Landlord”), pursuant to which the Company will lease approximately 10,795 square feet of office space located at 19 W. College Avenue, Suite 200, Yardley, PA 19067. The Company plans to relocate its headquarters to this location.…

Filed Mar 13, 2026Accepted Mar 13, 2026, 8:30 AM EDTCIK 1160308Accession 0001193125-26-105099
View company →Permanent SEC source ↗
Share

Company context

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Savara’s lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Savara’s management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

Current securities

SVRANASDAQ · EQUITY · Current

Recent company filings

  1. S-8 filingAug 11, 2026
  2. 10-Q filingAug 11, 2026
  3. 144 filingJun 22, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security HoldersJun 8, 2026
  5. 10-Q filingMay 12, 2026

Disclosure sections

Items 1.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01. Entry into a Material Definitive Agreement. On March 10, 2026, Savara Inc. (the “Company”) entered into an Agreement of Lease (the “Lease”) with ML7 Yardley Partners, LP (“Landlord”), pursuant to which the Company will lease approximately 10,795 square feet of office space located at 19 W. College Avenue, Suite 200, Yardley, PA 19067. The Company plans to relocate its headquarters to this location. The term of the Lease commences on July 1, 2026 and continues until December 1, 2031 (the “Term”). The Company has the option to extend the Term for an additional five-year term. The Company will make monthly base rent payments of approximately $28,337 for the first year of the Term, with annual increases of approximately 2%. The aggregate base rent over the Term is approximately $1,780,900, which reflects five months of rent abatement. In addition to the base rent, the Company will pay additional amounts to the Landlord related to the Company’s share of operating expenses, taxes, and utilities. The Company has paid a security deposit equal to $28,337. The Lease contains customary events of default, representations, warranties, and covenants. The foregoing description of the Lease is not complete and is qualified in its entirety by reference to the Lease, which is filed as Exhibit 10.1 hereto.